INDIANAPOLIS, Dec. 5, 2017 /PRNewswire/ -- Yesterday marked
dosing of the first patient with type 1 diabetes in a feasibility
study to evaluate the functionality and safety of an automated
insulin delivery (AID) system in development by Eli Lilly and
Company (NYSE: LLY). The AID system is part of the Connected
Diabetes Ecosystem, which is being designed to make diabetes
management easier by enabling people to use insulin more
effectively.
The AID system is a hybrid closed-loop platform that uses
connected devices – an insulin pump with a dedicated controller,
dosing algorithm, and continuous glucose monitor – to automate
insulin dosing. These components are designed to work together to
automatically adjust insulin infusion rates to maintain blood sugar
levels within a specified target range.
"This trial is a significant step forward for Lilly's Connected
Care program, moving the Connected Diabetes Ecosystem closer to
hopefully becoming available to the millions of people with
diabetes who need a simpler, more effective way to use insulin,"
said Marie Schiller, vice president,
Connected Care and site head, Cambridge Innovation Center.
The AID system is one of two platforms in development for the
Ecosystem. The other is an integrated insulin management system,
which combines a connected insulin pen with glucose-sensing
technologies and software applications to deliver personalized
insulin dose recommendations. Both platforms within the Ecosystem
are currently in development, and more clinical trials will be
initiated in the coming months in both people with type 1 and type
2 diabetes who use insulin. In conjunction with a variety of
partners, Lilly is working to make these platforms available to
patients within two to three years, pending FDA approval.
About Diabetes
Approximately 30 million
Americans1 and an estimated 425 million adults worldwide
have diabetes.2 Type 2 diabetes is the most common type,
accounting for an estimated 90 to 95 percent of all diabetes cases
in the United States.1
Diabetes is a chronic disease that occurs when the body does not
properly produce or use the hormone insulin.
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research, collaboration and quality
manufacturing, we strive to make life better for people affected by
diabetes. We offer a wide range of therapies and a continued
determination to provide real solutions—from medicines and
technologies to support programs and more. For the latest updates,
visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes
and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that met real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
This press release contains forward-looking statements about the
potential of automated insulin delivery (AID) systems and
integrated insulin management systems for the management and
treatment of diabetes, and reflects Lilly's current beliefs.
However, as with any pharmaceutical product or medical device,
there are substantial risks and uncertainties in the process of
development and commercialization. Among other things, there is no
guarantee that these platforms will be commercially successful or
that the company will meet its anticipated timelines for this study
of for the roll out of these platforms. For further discussion of
these and other risks and uncertainties, see Lilly's most recent
Form 10-K and Form 10-Q filings with the United States Securities
and Exchange Commission. Except as required by law, Lilly
undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
P-LLY
11/2017 Lilly USA, LLC 2017.
All rights reserved.
References
- Centers for Disease Control and Prevention. National Diabetes
Statistics Report, 2017. Available at:
https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
November 2017.
- International Diabetes Federation. IDF Diabetes Atlas, 8th edn,
2017. Available at: http://www.diabetesatlas.org/. November 2017.
Refer to: Jennifer
Hoopingarner, jennifer.hoopingarner@lilly.com,
317-741-8811
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-initiates-clinical-trial-to-evaluate-the-functionality-and-safety-of-its-automated-insulin-delivery-system-300566420.html
SOURCE Eli Lilly and Company